Preclinical data showed that tamibarotene selectively induced RARα target genes such as ITGAX, ITGAM, and CD38, and inhibits the proliferation in in vitro and patient-derived xenograft (PDX) models of leukemic cells with high RARα, but not in RARα-low AML cells. This evidence concerns the gene RARA and acute myeloid leukemia.